Trial Profile

Everolimus (RAD001) in Combination With Intravenous Carboplatin in Taxane- and Anthracycline-Pretreated Patients With Progressive Metastatic Breast Cancer.

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 27 Feb 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary) ; Carboplatin
Indications Advanced breast cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

22 Nov 2014 Status changed from completed to discontinued, according to European Clinical Trials Database record.
12 Jan 2013 Status changed from recruiting to completed as reported by European Clinical Trials Database.
21 Apr 2012 Planned number of patients changed from 54 to 58 as reported by EudraCT.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com